Bluebird Bio Inc. (BLUE) Given “Outperform” Rating at Wedbush
Wedbush restated their outperform rating on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note issued to investors on Wednesday morning. Wedbush currently has a $95.00 price objective on the stock.
A number of other analysts have also issued reports on the company. BMO Capital Markets assumed coverage on Bluebird Bio in a report on Thursday, November 10th. They issued a market perform rating and a $61.00 price target for the company. BTIG Research reiterated a buy rating and issued a $83.00 price target on shares of Bluebird Bio in a report on Monday, November 7th. Leerink Swann reiterated an outperform rating and issued a $80.00 price target on shares of Bluebird Bio in a report on Monday, November 7th. JPMorgan Chase & Co. reiterated a buy rating on shares of Bluebird Bio in a report on Monday, November 7th. Finally, Piper Jaffray Cos. reiterated an overweight rating and issued a $95.00 price target on shares of Bluebird Bio in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $82.82.
Bluebird Bio (NASDAQ:BLUE) remained flat at $62.50 during mid-day trading on Wednesday. The company’s stock had a trading volume of 992,930 shares. The firm’s market capitalization is $2.33 billion. The firm’s 50-day moving average is $56.86 and its 200-day moving average is $52.51. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $95.28.
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.59) by $0.48. Bluebird Bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.82 million. During the same quarter last year, the firm earned ($1.18) EPS. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. Equities research analysts forecast that Bluebird Bio will post ($7.05) EPS for the current fiscal year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the transaction, the insider now owns 5,891 shares of the company’s stock, valued at approximately $394,697. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of BLUE. Price T Rowe Associates Inc. MD boosted its position in shares of Bluebird Bio by 37.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 3,365,797 shares of the company’s stock valued at $228,134,000 after buying an additional 921,416 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Bluebird Bio by 143.8% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 7,800 shares of the company’s stock valued at $528,000 after buying an additional 4,600 shares in the last quarter. Credit Suisse AG boosted its position in shares of Bluebird Bio by 9.3% in the third quarter. Credit Suisse AG now owns 101,322 shares of the company’s stock valued at $6,869,000 after buying an additional 8,656 shares in the last quarter. Chartwell Investment Partners LLC acquired a new position in shares of Bluebird Bio during the third quarter valued at approximately $2,830,000. Finally, Baker BROS. Advisors LP acquired a new position in shares of Bluebird Bio during the third quarter valued at approximately $19,923,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.